Post-Market Surveillance With a Novel mHealth Platform

Overview

About this study

This is a study to pilot the feasibility of using a novel patient-led, smartphone-based mobile health platform (Hugo) for real-world surveillance of outcomes of patients after sleeve gastrectomy and catheter-base atrial fibrillation ablation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age >18
  • English-speaking
  • Planned for either sleeve gastrectomy or catheter-based atrial fibrillation ablation
  • Participant is willing and able to read and sign consent and participate in study
  • Participant has an email account and a mobile device (smartphone or tablet) able to download the necessary applications
  • Participant is willing to use the mobile health platform and syncable devices (e.g. Fitbit Charge 2)
  • Attending bariatric surgeon or electrophysiologist (as appropriate) concurs that patient is a candidate for enrollment

Exclusion Criteria:

  • Healthy patients
  • Patients who refuse participation

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Nilay Shah, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions